BioSpace has highlighted four next-generation Alzheimer's disease treatment candidates that may hold promise[1]. The Alzheimer's disease screening test uses a finger prick blood sample and will be evaluated as part of the Global Alzheimer's Disease Platform[1]. The European Medicines Agency has approved the drug Kisunla, which aims to remove harmful protein deposits in the brain typical of Alzheimer's disease[1][5]. After Leqembi, Kisunla is the second medicine that directly attacks the cause of the disease, not just the symptoms[1][2][5]. According to clinical studies, Leqembi slowed cognitive decline in early-stage patients by 27 percent compared to placebo[2]. Research has revealed serious side effects of Kisunla, including death[1]. Other candidates include ALZ-801, whose key study results are expected to be published in April 2025[6].